menu
    • menu
    [{"orgOrder":0,"company":"Ossianix","sponsor":"Attralus","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody-peptide Conjugate","year":"2022","type":"Licensing Agreement","leadProduct":"AT-04","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Ossianix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ossianix \/ Attralus","highestDevelopmentStatusID":"4","companyTruncated":"Ossianix \/ Attralus"},{"orgOrder":0,"company":"Ossianix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ossianix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ossianix \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Ossianix \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Ossianix

    Menu

    Ossianix

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ossianix

                            United Kingdom arrow
                            FNCE
                            Not Confirmed

                            Ossianix

                            United Kingdom arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT-04

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Attralus

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Deliv...

                            Details : Under the terms of the agreement, Attralus will use the patented VNAR antibody developed by Ossianix to help deliver AT-04, its developmental pan-amyloid removal (PAR) therapeutic candidate, across the BBB to the brain.

                            Product Name : Undisclosed

                            Product Type : Antibody-peptide Conjugate

                            Upfront Cash : Undisclosed

                            November 17, 2022

                            Lead Product(s) : AT-04

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Attralus

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ossianix

                            United Kingdom arrow
                            FNCE
                            Not Confirmed

                            Ossianix

                            United Kingdom arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ossianix is Responding to the COVID-19 Pandemic by Developing Therapeutic Single Domain VNAR Antibodies

                            Details : A novel approach being pioneered at Ossianix uses its patented VNAR phage display libraries to identify single domain antibodies with high affinity and specificity against the COVID-19 spike protein.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 02, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth